Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL

NCT05940961 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

ALL
MRD-positive
Hematopoietic Stem Cell Transplantation

Interventions

DRUG: Inotuzumab Ozogamicin

Sponsor

Sheng-Li Xue, MD

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]